Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer's Disease at AD/PD 2023 Seite 1
21.03.2023 - - CEO Participating on Panel Hosted by Alzheimer’s Drug Discovery Foundation -NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) - Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be presenting results of a proteomic biomarker meta-analysis of ... Seite 1
Source: wallstreet-online.de